NATUREVIEW
REVIEWS AND COMMENT FROM THE NATURE PUBLISHING GROUP

▲ **Taking aim at pharma.** Snyderman, R. *Nature Medicine* December (2004). **A review of the book *The Truth About the Drug Companies: How They Deceive Us and What to Do About It* by M. Angell.**



▲ **Rational targeting for prion therapeutics.**
Mallucci, G. & Collinge, J.
Nature Reviews Neuroscience
January (2005)

• **Tuberculosis — metabolism and respiration in the absence of growth.**
Boshoff, H. I. M. & Barry, C. E.
Nature Reviews Microbiology
January (2005)
This article reviews the metabolic adaptations that *Mycobacterium tuberculosis* uses to survive and how knowledge of these pathways might help in the search for new therapeutic interventions for tuberculosis.

• **Integrin-linked kinase: a cancer therapeutic target unique amongst its ilk.**
Hannigan, G., Troussard, A. A. & Dedhar, S.
Nature Reviews Cancer
January (2005)

• **Cellular immunotherapy for viral infection after haematopoietic stem-cell transplantation.**
Moss, P. & Rickinson, A.
Nature Reviews Immunology
January (2005)

• **Creating incentives for genomic research to improve targeting of therapies.**
Evans, B. J., Flockhart, D. A. & Meslin, E. M.
Nature Medicine
December (2004)

• **Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering.**
Lutolf, M. P. & Hubbell, J. A.
Nature Biotechnology
January (2005)

• **Cancer drug discovery: the wisdom of imprecision.**
Gudkov, A. V.
Nature Medicine
December (2004)

• **Chemotherapy and the war on cancer.**
Chabner, B. A. & Roberts, T. G.
Nature Reviews Cancer
January (2005)

• **An enriched look at tyrosine phosphorylation.**
Conrads, T. P. & Veenstra, T. D.
Nature Biotechnology
January (2005)

▼ **Combination stroke therapy: easy as APC?**
Lo, E. H.
Nature Medicine
December (2004)
So far, the only FDA-approved therapy for ischaemic stroke is recombinant tissue plasminogen activator (tPA), which can increase blood flow to damaged brain tissue. However, this is associated with severe side effects and must be administered shortly after stroke. As discussed in this News and Views article, combining the drug with activated protein C (APC) might provide a solution.